Over the past years, certain indices of inflammatory cells including neutrophil-to-lymphocyte ratio (NLR) have been extensively studied as simple measures of systemic inflammation in the clinical setting.[@bib1] On the other hand, systemic inflammation is well known to be associated with a variety of life-threatening conditions including acute coronary syndromes, cardiac arrhythmias, and new onset or worsening heart failure (HF).[@bib1], [@bib2], [@bib3] In their recently published article, Khalil et al have demonstrated the particular clinical value of NLR in predicting major cardiovascular events, HF admissions along with all-cause mortality at one-year after transcatheter aortic valve implantation (TAVI).[@bib1] Accordingly, a pre-TAVI NLR value of ≥4 was identified as significantly predictive of these adverse events in the post-TAVI setting.[@bib1] The authors[@bib1] should be congratulated for further substantiating the association between systemic inflammation (as demonstrated with high NLR values) and poor cardiovascular outcomes specifically in a subset of high-risk and fragile subjects. However, I would like to focus on the converse perspective in this setting and make a few comments regarding the auspicious consequences of low NLR values including left ventricular reverse remodeling (LVRR) among TAVI recipients with HF.

In clinical practice, LVRR, unlike adverse myocardial remodeling,[@bib4], [@bib5] has been considered as an auspicious sign probably with the highest prognostic benefit among patients with systolic HF.[@bib6], [@bib7], [@bib8] In this setting, it is universally defined as a gradual improvement in left ventricular ejection fraction values (as demonstrated with an increment of ≥15% or an increment of ≥10% accompanied by a substantial diminution of end-systolic diameter or volume index within one-year as compared with baseline values).[@bib6], [@bib7], [@bib8] Within this context, LVRR might potentially emerge spontaneously particularly in the presence of proper systemic milieu harboring a blunted inflammatory and mitogenic response or might more commonly arise after hemodynamic relief of certain valvular pathologies including aortic stenosis (AS), and so on.[@bib6], [@bib7], [@bib8], [@bib9] However, it is also well known that LVRR might not be encountered even after correction of the culprit valvular pathology in a significant portion of subjects with left ventricular (LV) systolic dysfunction[@bib9] (even with favorable features including moderate LV impairment with a short duration, etc) suggesting the potential impact of an inadvertent milieu with high systemic inflammatory burden in this setting: accordingly, elevation of certain cytokines including hepatocyte growth factor (HPG) at baseline were recently reported to be associated with reduced recovery of LV functions (as measured with a variety of more sensitive echocardiographic indices including global longitudinal strain (LGS), etc.) at 1-year following TAVI.[@bib10]

Given the high prevalance of systolic HF (with high- or occasionally low-gradient AS) among TAVI recipients (for e.g., approximately one-third of the whole study population in the study by Khalil et al),[@bib1] evolution of LVRR in these patients might also have important implications that might potentially be addressed by the present study.[@bib1]

First, as expected, a portion of TAVI recipients with systolic HF might incur LVRR after correction of transaortic gradient,[@bib9] particularly if the AS substantially accounts for the evolution of systolic dysfunction. Accordingly, what was the incidence of LVRR at one year in patients with a baseline systolic HF in the study?[@bib1]

Second, low systemic inflammation as measured with low NLR values, on top of the impact of mechanical relief of AS, might create a significant proclivity for the emergence of LVRR (and possibly in a more striking manner) among TAVI recipients with a preexisting systolic HF. Accordingly, was there an association between LVRR (if any) and low NLR values in the study? Was there a certain cut-off value of pre-TAVI NLR, below which it is feasible to highly predict LVRR at one year?

And finally, LVRR is well known to be associated with a substantial prognostic benefit[@bib9] regardless of the underlying cause of systolic HF. Therefore, how was the prognosis among HF patients with LVRR as compared with those without LVRR at one year? Did LVRR serve as an independent favorable prognostic factor (if so) or appear to be dependent, at least to some extent, on certain factors including low NLR values in the study?[@bib1]
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